Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Brivanib in Recurrent Ovarian Cancer
NCT03895788Phase 1Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of niraparib and brivanib in ovarian cancer, sponsored by Hunan Cancer Hospital. Primary endpoint: Maximum Tolerated Dose at 1 year. Status: unknown.
02
Drugs
niraparibbrivanib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03895788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895788.